PRELIMINARY NOVEMBER 2022 THERAPEUTIC DRUG CLASSES

ALZHEIMER'S AGENTS

ANTICONVULSANTS

ANTIDEPRESSANTS, OTHER

ANTIDEPRESSANTS, SSRIs

ANTIHISTAMINES, MINIMALLY SEDATING

ANTIHYPERTENSIVES, SYMPATHOLYTIC

ANTIHYPERURICEMICS, ORAL

ANTIPARKINSON'S AGENTS

ANTIPSORIATICS, ORAL

ANTIPSORIATICS, TOPICAL

ANTIPSYCHOTICS (ORAL AND INJECTABLE)

ANXIOLYTICS

BILE SALTS

BRONCHODILATORS, BETA AGONIST

COPD AGENTS

COUGH AND COLD/NARCOTICS

CYTOKINE AND CAM ANTAGONISTS

EPINEPHRINE, SELF-INJECTED

ERYTHROPOIESIS STIMULATING PROTEINS

GLUCOCORTICOIDS, INHALED

GLUCOCORTICOIDS, ORAL

HISTAMINE II RECEPTOR BLOCKERS

IDIOPATHIC PULMONARY FIBROSIS - Potential New Class

IMMUNOMODULATORS, ASTHMA

IMMUNOMODULATORS FOR ATOPIC DERMATITIS

IMMUNOMODULATORS, TOPICAL

INTRANASAL RHINITIS AGENTS

LEUKOTRIENE MODIFIERS

METHOTREXATE

MOVEMENT DISORDERS

NEUROPATHIC PAIN (ANALGESICS/ANESTHETICS TOPICAL AND FIBROMYALGIA)

NSAIDS

OPHTHALMIC ANTIBIOTICS

OPHTHALMIC ANTIBIOTIC/STEROID COMBINATIONS

OPHTHALMIC ANTIINFLAMMATORIES

OPHTHALMICS, ANTI-INFLAMMATORY/IMMUNOMODULATOR

OPHTHALMICS FOR ALLERGIC CONJUNCTIVITIS

OPHTHALMICS, GLAUCOMA AGENTS

OTIC ANTIBIOTICS

OTIC ANTI-INFECTIVES

SEDATIVE HYPNOTICS

SICKLE CELL ANEMIA TREATMENTS

STEROIDS, TOPICAL-HIGH POTENCY

STEROIDS, TOPICAL-LOW POTENCY

STEROIDS, TOPICAL-MEDIUM POTENCY

STEROIDS, TOPICAL-VERY HIGH POTENCY

STIMULANTS AND RELATED AGENTS